Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
We explore four peptides that have attracted attention: Thymosin Alpha1, BPC157, KPV, and Thymosin Beta 4
Safety Profile: Preclinical data indicate a wide safety margin for BPC-157 (no lethal dose up to ~20 mg/kg)
Moreover, ADCs can also stimulate the immune-cell effector function and disrupt receptors dimerization [3]
In moderate to severe TBI the signaling pathways become more complicated, and there are many potential pathways that can be targeted and blocked for therapeutic intervention like IL-6, TNFa, TLRs, S100 (DAMPs), RAGE, JAK2/STAT3, and/or VEGF/MET to prevent neuroglial overactivation, neuroinflammation, gliosis, loss of inhibition, synaptic knock-down, cell death, and chemokine secretion, and we hope to conduct further research on these conditions (2a)
